Patents, Bioethics and the Human Body: Reconceptualising Bioethics in Patent Decision-Making and the Governance Function of Patents
PatentsInHumans aims to integrate bioethics into patent decision-making for body-related technologies, addressing ethical implications and proposing governance reforms.
Projectdetails
Introduction
PatentsInHumans challenges the current marginalisation of bioethics in patent decision-making for technologies related to the human body. A patent gives a rightsholder the right to stop others from using a patented technology. This allows them to control how that technology is provided, to whom, and on what terms.
Bioethical Issues
Where patents are for technologies related to the body, this control poses considerable bioethical issues because patents can affect how we treat, use, and modify bodies. Yet patent systems generally do not engage with such implications. All patents are treated the same, regardless of the underlying technology; for example, a patent on an engine part is treated the same as a patent on a medicine, despite the significant effects the latter has for health.
Self-Reinforcing Cycle
PatentsInHumans proposes that there is a self-reinforcing cycle where:
- Patents are granted even if bioethical implications are posed by patents over such technologies.
- There are limited incentives for rightsholders to license patents in a way that addresses bioethical implications.
- Patents, once granted, are difficult to challenge if bioethical issues arise.
Radical Reconceptualisation
PatentsInHumans radically reconceptualises patents as governance devices over the body in such contexts. It proposes that when patents are applied for, the underlying technology’s relationship to the body must be considered.
Evaluation of Bioethical Implications
The project will therefore evaluate the bioethical implications that patents over such technologies have for how we treat, use, or modify our bodies. These implications must guide patent decision-making and the adoption of licensing or grant conditions that pre-empt bioethical issues.
Cross-Disciplinary Institutional Analysis
The project develops a cross-disciplinary institutional analysis to evaluate key legal, structural, and cultural barriers leading to the marginalisation of bioethics in patent decision-making. It aims to formulate pathways to bring bioethics into patent decision-making for technologies related to the body, with important conceptual and policy implications.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.958 |
Totale projectbegroting | € 1.499.958 |
Tijdlijn
Startdatum | 1-11-2022 |
Einddatum | 31-10-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- NATIONAL UNIVERSITY OF IRELAND MAYNOOTHpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Economics of Health Care Markets and InnovationThis research program aims to analyze and develop optimal public policies and pricing mechanisms to ensure equitable access to innovative healthcare while addressing cross-country economic challenges. | ERC Advanced... | € 1.421.250 | 2024 | Details |
Human collaboration with AI agents in national health governance: organizational circumstances under which data analysts and medical experts follow or deviate from AI.This project aims to explore the socio-cultural dynamics of AI in health governance across six countries to develop a theory on ethical AI intervention and its impact on national health policies. | ERC Starting... | € 1.499.961 | 2023 | Details |
Health Simulations: Ethical and Societal Challenges of Digital TwinsSIMTWIN aims to analyze the ethical and societal implications of Digital Twins in healthcare to develop a robust governance framework for their use in health simulations. | ERC Starting... | € 1.497.275 | 2023 | Details |
Human based bioinks to engineer physiologically relevant tissuesHumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing. | ERC Proof of... | € 150.000 | 2022 | Details |
Beyond Thalidomide: The Patient as an Agent of ChangeBeyond Thalidomide aims to document the historical rise of patient engagement in drug-related disabilities, reshaping reproductive health discourse through global case studies and digital storytelling. | ERC Starting... | € 1.499.743 | 2025 | Details |
Economics of Health Care Markets and Innovation
This research program aims to analyze and develop optimal public policies and pricing mechanisms to ensure equitable access to innovative healthcare while addressing cross-country economic challenges.
Human collaboration with AI agents in national health governance: organizational circumstances under which data analysts and medical experts follow or deviate from AI.
This project aims to explore the socio-cultural dynamics of AI in health governance across six countries to develop a theory on ethical AI intervention and its impact on national health policies.
Health Simulations: Ethical and Societal Challenges of Digital Twins
SIMTWIN aims to analyze the ethical and societal implications of Digital Twins in healthcare to develop a robust governance framework for their use in health simulations.
Human based bioinks to engineer physiologically relevant tissues
HumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing.
Beyond Thalidomide: The Patient as an Agent of Change
Beyond Thalidomide aims to document the historical rise of patient engagement in drug-related disabilities, reshaping reproductive health discourse through global case studies and digital storytelling.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bacteria Biofilm as bio-factory for tissue regenerationBIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes. | EIC Pathfinder | € 2.903.862 | 2023 | Details |
BioStealthHet project onderzoekt of BioStealth-oppervlaktetechnologie de bloedcontacteigenschappen van cardiovasculaire implantaten kan verbeteren, met als doel de veiligheid en prestaties van medische apparaten te verhogen. | Mkb-innovati... | € 20.000 | 2023 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
Organ on a chip platform for drug discoveryBI/OND ontwikkelt innovatieve hardwareoplossingen voor organen op een chip om gepersonaliseerde medicijnen te bevorderen en het gebruik van dieren in pre-klinisch onderzoek te verminderen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research. | EIC Pathfinder | € 1.225.468 | 2024 | Details |
Bacteria Biofilm as bio-factory for tissue regeneration
BIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes.
BioStealth
Het project onderzoekt of BioStealth-oppervlaktetechnologie de bloedcontacteigenschappen van cardiovasculaire implantaten kan verbeteren, met als doel de veiligheid en prestaties van medische apparaten te verhogen.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
Organ on a chip platform for drug discovery
BI/OND ontwikkelt innovatieve hardwareoplossingen voor organen op een chip om gepersonaliseerde medicijnen te bevorderen en het gebruik van dieren in pre-klinisch onderzoek te verminderen.
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.
Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research.